Evogene Ltd EVGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVGN is a good fit for your portfolio.
News
-
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
-
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
-
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
-
Evogene Announces Filing of Annual Report on Form 20-F
-
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
-
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
-
Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America
-
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $0.69
- Day Range
- $0.63–0.68
- 52-Week Range
- $0.45–1.44
- Bid/Ask
- $0.65 / $0.67
- Market Cap
- $33.26 Mil
- Volume/Avg
- 78,590 / 174,824
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.67
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 143
- Website
- https://www.evogene.com
Comparables
Valuation
|
Metric
|
EVGN
|
DRTS
|
ABCL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.94 | 2.22 | 0.99 |
Price/Sales | 5.67 | — | 29.81 |
Price/Cash Flow | — | — | — |
Price/Earnings
EVGN
DRTS
ABCL
Financial Strength
|
Metric
|
EVGN
|
DRTS
|
ABCL
|
|---|---|---|---|
Quick Ratio | 4.82 | 11.56 | 6.93 |
Current Ratio | 4.96 | 12.07 | 7.33 |
Interest Coverage | −235.83 | −451.95 | — |
Quick Ratio
EVGN
DRTS
ABCL
Profitability
|
Metric
|
EVGN
|
DRTS
|
ABCL
|
|---|---|---|---|
Return on Assets (Normalized) | −44.62% | −21.92% | −6.10% |
Return on Equity (Normalized) | −125.94% | −26.10% | −7.74% |
Return on Invested Capital (Normalized) | −57.49% | −27.78% | −10.03% |
Return on Assets
EVGN
DRTS
ABCL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bpnzmkthqz | Jrfy | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gcqzhppk | Dszmw | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Prfqvkbb | Ctxhmb | $98.9 Bil | |
MRNA
| Moderna Inc | Kmfyrgwc | Tgnh | $39.7 Bil | |
ARGX
| argenx SE ADR | Fcnxtlv | Qhq | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Ppltdbw | Mygys | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wbqkjhg | Nnynsy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bkxdpnsc | Pfzsf | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cfrvcyvclr | Ymsqwk | $12.3 Bil | |
INCY
| Incyte Corp | Dnqpxckf | Dkbvlfg | $11.8 Bil |